Search

Your search keyword '"Iannone F"' showing total 1,380 results
Start Over Author "Iannone F"
1,380 results on '"Iannone F"'

202. OP0231 COMPARATIVE EFFECTIVENESS OF JAK-INHIBITORS, TNF-INHIBITORS, ABATACEPT AND IL-6 INHIBITORS IN AN INTERNATIONAL COLLABORATION OF REGISTERS OF RHEUMATOID ARTHRITIS PATIENTS (THE “JAK-POT” STUDY)

Author

Lauper, K., primary, Mongin, D., additional, Bergstra, S. A., additional, Choquette, D., additional, Codreanu, C., additional, De Cock, D., additional, Dreyer, L., additional, Elkayam, O., additional, Hyrich, K., additional, Iannone, F., additional, Inanc, N., additional, Kristianslund, E., additional, Kvien, T. K., additional, Leeb, B., additional, Lukina, G., additional, Nordström, D., additional, Pavelka, K., additional, Pombo-Suarez, M., additional, Rotar, Z., additional, Santos, M. J., additional, Strangfeld, A., additional, Courvoisier, D., additional, and Finckh, A., additional

Published
2020
Full Text
View/download PDF

203. FRI0239 ANTI-NXP2 ANTIBODIES: CLINICAL AND SEROLOGICAL ASSOCIATIONS IN A MULTICENTRIC ITALIAN STUDY

Author

Fredi, M., primary, Cavazzana, I., additional, Ceribelli, A., additional, Lazzaroni, M. G., additional, Barsotti, S., additional, Benucci, M., additional, Cavagna, L., additional, De Stefano, L., additional, Doria, A., additional, Emmi, G., additional, Fornaro, M., additional, Furini, F., additional, Gerli, R., additional, Giudizi, M. G., additional, Govoni, M., additional, Ghirardello, A., additional, Iaccarino, L., additional, Iannone, F., additional, Infantino, M., additional, Mathieu, A., additional, Marasco, E., additional, Migliorini, P., additional, Palterer, B., additional, Parronchi, P., additional, Piga, M., additional, Pratesi, F., additional, Radice, A., additional, Selmi, C., additional, Riccieri, V., additional, Tampoia, M., additional, Zanframundo, G., additional, Tincani, A., additional, and Franceschini, F., additional

Published
2020
Full Text
View/download PDF

205. SAT0430 SECUKINUMAB EFFECTIVENESS IN 1543 PATIENTS WITH PSORIATIC ARTHRITIS TREATED IN ROUTINE CLINICAL PRACTICE IN 13 EUROPEAN COUNTRIES IN THE EuroSpA RESEARCH COLLABORATION NETWORK

Author

Michelsen, B., primary, Georgiadis, S., additional, DI Giuseppe, D., additional, Loft, A. G., additional, Nissen, M., additional, Iannone, F., additional, Pombo-Suarez, M., additional, Mann, H., additional, Rotar, Z., additional, Eklund, K., additional, Kvien, T. K., additional, Santos, M. J., additional, Gudbjornsson, B., additional, Codreanu, C., additional, Yilmaz, S., additional, Wallman, J. K., additional, Brahe, C. H., additional, Moeller, B., additional, Favalli, E. G., additional, Sánchez-Piedra, C., additional, Nekvindova, L., additional, Tomsic, M., additional, Trokovic, N., additional, Kristianslund, E., additional, Santos, H., additional, Love, T., additional, Ionescu, R., additional, Pehlivan, Y., additional, Jones, G. T., additional, Van der Horst-Bruinsma, I., additional, Midtbøll Ørnbjerg, L., additional, Ǿstergaard, M., additional, and Hetland, M. L., additional

Published
2020
Full Text
View/download PDF

206. THU0398 DRUG RETENTION RATES AND TREATMENT OUTCOMES IN 1860 AXIAL SPONDYLOARTHRITIS PATIENTS TREATED WITH SECUKINUMAB IN ROUTINE CLINICAL PRACTICE IN 13 EUROPEAN COUNTRIES IN THE EUROSPA RESEARCH COLLABORATION NETWORK

Author

Michelsen, B., primary, Lindström, U., additional, Codreanu, C., additional, Ciurea, A., additional, Zavada, J., additional, Loft, A. G., additional, Pombo-Suarez, M., additional, Onen, F., additional, Kvien, T. K., additional, Rotar, Z., additional, Santos, M. J., additional, Iannone, F., additional, Hokkanen, A. M., additional, Gudbjornsson, B., additional, Askling, J., additional, Ionescu, R., additional, Nissen, M., additional, Pavelka, K., additional, Sánchez-Piedra, C., additional, Akar, S., additional, Sexton, J., additional, Tomsic, M., additional, Santos, H., additional, Sebastiani, M., additional, Osterlund, J., additional, Geirsson, A. J., additional, Jones, G. T., additional, Van der Horst-Bruinsma, I., additional, Georgiadis, S., additional, Brahe, C. H., additional, Midtbøll Ørnbjerg, L., additional, Hetland, M. L., additional, and Ǿstergaard, M., additional

Published
2020
Full Text
View/download PDF

208. SAT0348 CLINICAL SPECTRUM TIME COURSE OF ANTISYNTHETASE SYNDROME PATIENTS POSITIVE FOR ANTICENTROMERE ANTIBODIES

Author

Zanframundo, G., primary, Sambataro, G., additional, Codullo, V., additional, Biglia, A., additional, Bozzalla Cassione, E., additional, Bravi, E., additional, Iannone, F., additional, Fornaro, M., additional, Triantafyllias, K., additional, Pesci, A., additional, Tomietto, P., additional, Molberg, Ø., additional, Scarpato, S., additional, Voll, R., additional, Matucci-Cerinic, M., additional, González-Gay, M. A., additional, Montecucco, C., additional, and Cavagna, L., additional

Published
2020
Full Text
View/download PDF

210. FRI0283 CO-MEDICATION WITH CSDMARD HAS LITTLE EFFECT ON THE RETENTION OF TNF INHIBITORS IN PSORIATIC ARTHRITIS, RESULTS FROM THE EUROSPA COLLABORATION

Author

Lindström, U., primary, DI Giuseppe, D., additional, Delcoigne, B., additional, Glintborg, B., additional, Moeller, B., additional, Pombo-Suarez, M., additional, Sánchez-Piedra, C., additional, Eklund, K., additional, Relas, H., additional, Gudbjornsson, B., additional, Love, T., additional, Jones, G. T., additional, Ciurea, A., additional, Codreanu, C., additional, Ionescu, R., additional, Nekvindova, L., additional, Zavada, J., additional, Atas, N., additional, Yolbaş, S., additional, Fagerli, K., additional, Michelsen, B., additional, Rotar, Z., additional, Tomsic, M., additional, Iannone, F., additional, Santos, M. J., additional, Ávila-Ribeiro, P., additional, Midtbøll Ørnbjerg, L., additional, Ǿstergaard, M., additional, Jacobsson, L. T. H., additional, Askling, J., additional, and Nissen, M., additional

Published
2020
Full Text
View/download PDF

211. THU0344 CLINICAL AND HISTOLOGICAL SPECTRUM OF ANTI-MI2 DERMATOMYOSITIS: A MULTICENTRE RETROSPECTIVE COHORT

Author

Fornaro, M., primary, Girolamo, F., additional, Cavagna, L., additional, Franceschini, F., additional, Giannini, M., additional, Zanframundo, G., additional, Fredi, M., additional, Tampoia, M., additional, Amati, A., additional, Serlenga, L., additional, Lia, A., additional, Moschetti, L., additional, Dabbicco, D., additional, Coladonato, L., additional, and Iannone, F., additional

Published
2020
Full Text
View/download PDF

212. OP0198 A SYSTEMATIC REVIEW TO INFORM THE EULAR POINTS TO CONSIDER WHEN ANALYSING AND REPORTING COMPARATIVE EFFECTIVENESS RESEARCH WITH OBSERVATIONAL DATA IN RHEUMATOLOGY

Author

Lauper, K., primary, Kedra, J., additional, De Wit, M., additional, Fautrel, B., additional, Frisell, T., additional, Hyrich, K., additional, Iannone, F., additional, Machado, P. M., additional, Midtbøll Ørnbjerg, L., additional, Rotar, Z., additional, Santos, M. J., additional, Stamm, T., additional, Stones, S., additional, Strangfeld, A., additional, Landewé, R. B. M., additional, Finckh, A., additional, Bergstra, S. A., additional, and Courvoisier, D., additional

Published
2020
Full Text
View/download PDF

213. OP0199 POINTS TO CONSIDER WHEN ANALYSING AND REPORTING COMPARATIVE EFFECTIVENESS RESEARCH WITH OBSERVATIONAL DATA IN RHEUMATOLOGY

Author

Courvoisier, D., primary, Lauper, K., additional, Bergstra, S. A., additional, De Wit, M., additional, Fautrel, B., additional, Frisell, T., additional, Hyrich, K., additional, Iannone, F., additional, Kedra, J., additional, Machado, P. M., additional, Midtbøll Ørnbjerg, L., additional, Rotar, Z., additional, Santos, M. J., additional, Stamm, T., additional, Stones, S., additional, Strangfeld, A., additional, Landewé, R. B. M., additional, and Finckh, A., additional

Published
2020
Full Text
View/download PDF

214. OP0109 CO-MEDICATION WITH A CONVENTIONAL SYNTHETIC DMARD IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS IS ASSOCIATED WITH IMPROVED RETENTION OF TNF INHIBITORS: RESULTS FROM THE EUROSPA COLLABORATION

Author

Nissen, M., primary, Delcoigne, B., additional, DI Giuseppe, D., additional, Jacobsson, L. T. H., additional, Fagerli, K., additional, Loft, A. G., additional, Ciurea, A., additional, Nordström, D., additional, Rotar, Z., additional, Iannone, F., additional, Santos, M. J., additional, Pombo-Suarez, M., additional, Gudbjornsson, B., additional, Mann, H., additional, Akkoc, N., additional, Codreanu, C., additional, Van der Horst-Bruinsma, I., additional, Michelsen, B., additional, Macfarlane, G., additional, Hetland, M. L., additional, Tomsic, M., additional, Moeller, B., additional, Ávila-Ribeiro, P., additional, Sánchez-Piedra, C., additional, Relas, H., additional, Geirsson, A. J., additional, Nekvindova, L., additional, Yildirim Cetin, G., additional, Ionescu, R., additional, Steen Krogh, N., additional, Askling, J., additional, Glintborg, B., additional, and Lindström, U., additional

Published
2020
Full Text
View/download PDF

216. Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study

Author

Sota J, Vitale A, Insalaco A, Sfriso P, Lopalco G, Emmi G, Cattalini M, Manna R, Cimaz R, Priori R, Talarico R, de Marchi G, Frassi M, Gallizzi R, Soriano A, Alessio M, Cammelli D, Maggio MC, Gentileschi S, Marcolongo R, La Torre F, Fabiani C, Colafrancesco S, Ricci F, Galozzi P, Viapiana O, Verrecchia E, Pardeo M, Cerrito L, Cavallaro E, Olivieri AN, Paolazzi G, Vitiello G, Maier A, Silvestri E, Stagnaro C, Valesini G, Mosca M, de Vita S, Tincani A, Lapadula G, Frediani B, De Benedetti F, Iannone F, Punzi L, Salvarani C, Galeazzi M, Angotti R, Messina M, Tosi GM, Rigante, Sota, J, Vitale, A, Insalaco, A, Sfriso, P, Lopalco, G, Emmi, G, Cattalini, M, Manna, R, Cimaz, R, Priori, R, Talarico, R, de Marchi, G, Frassi, M, Gallizzi, R, Soriano, A, Alessio, M, Cammelli, D, Maggio, Mc, Gentileschi, S, Marcolongo, R, La Torre, F, Fabiani, C, Colafrancesco, S, Ricci, F, Galozzi, P, Viapiana, O, Verrecchia, E, Pardeo, M, Cerrito, L, Cavallaro, E, Olivieri, An, Paolazzi, G, Vitiello, G, Maier, A, Silvestri, E, Stagnaro, C, Valesini, G, Mosca, M, de Vita, S, Tincani, A, Lapadula, G, Frediani, B, De Benedetti, F, Iannone, F, Punzi, L, Salvarani, C, Galeazzi, M, Angotti, R, Messina, M, Tosi, Gm, and Rigante

Published
2018

217. Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real life clinical practice: a nationwide multicenter retrospective observational study

Author

Sota, J, Vitale, A, Insalaco, A, Sfriso, P, Lopalco, G, Emmi, G, Cattalini, M, Manna, R, Cimaz, R, Priori, R, Talarico, R, de Marchi, G, Frassi, M, Gallizzi, R, Soriano, A, Alessio, M, Cammelli, D, Maggio, Mc, Gentileschi, S, Marcolongo, R, La Torre, F, Fabiani, C, Colafrancesco, S, Ricci, F, Galozzi, P, Viapiana, O, Verrecchia, E, Pardeo, M, Cerrito, L, Cavallaro, E, Olivieri, An, Paolazzi, G, Vitiello, G, Maier, A, Silvestri, E, Stagnaro, C, Valesini, G, Mosca, M, de Vita, S, Tincani, A, Lapadula, G, Frediani, B, De Benedetti, F, Iannone, F, Punzi, L, Salvarani, C, Galeazzi, M, Angotti, R, Messina, M, Tosi, Gm, Rigante, D, Cantarini, L, 'Working Group' of Systemic Autoinflammatory Diseases of SIR (Italian Society of, Rheumatology)., Sota, J., Vitale, A., Insalaco, A., Sfriso, P., Lopalco, G., Emmi, G., Cattalini, M., Manna, R., Cimaz, R., Priori, R., Talarico, R., de Marchi, G., Frassi, M., Gallizzi, R., Soriano, A., Alessio, M., Cammelli, D., Maggio, M. C., Gentileschi, S., Marcolongo, R., La Torre, F., Fabiani, C., Colafrancesco, S., Ricci, F., Galozzi, P., Viapiana, O., Verrecchia, E., Pardeo, M., Cerrito, L., Cavallaro, E., Olivieri, A. N., Paolazzi, G., Vitiello, G., Maier, A., Silvestri, E., Stagnaro, C., Valesini, G., Mosca, M., de Vita, S., Tincani, A., Lapadula, G., Frediani, B., De Benedetti, F., Iannone, F., Punzi, L., Salvarani, C., Galeazzi, M., Angotti, R., Messina, M., Tosi, G. M., Rigante, D., Cantarini, L., Sota, Jurgen, Vitale, Antonio, Insalaco, Antonella, Sfriso, Paolo, Lopalco, Giuseppe, Emmi, Giacomo, Cattalini, Marco, Manna, Raffaele, Cimaz, Rolando, Priori, Roberta, Talarico, Rosaria, de Marchi, Ginevra, Frassi, Micol, Gallizzi, Romina, Soriano, Alessandra, Alessio, Maria, Cammelli, Daniele, Maggio, Maria Cristina, Gentileschi, Stefano, Marcolongo, Renzo, La Torre, Francesco, Fabiani, Claudia, Colafrancesco, Serena, Ricci, Francesca, Galozzi, Paola, Viapiana, Ombretta, Verrecchia, Elena, Pardeo, Manuela, Cerrito, Lucia, Cavallaro, Elena, Olivieri, Alma Nunzia, Paolazzi, Giuseppe, Vitiello, Gianfranco, Maier, Armin, Silvestri, Elena, Stagnaro, Chiara, Valesini, Guido, Mosca, Marta, de Vita, Salvatore, Tincani, Angela, Lapadula, Giovanni, Frediani, Bruno, De Benedetti, Fabrizio, Iannone, Florenzo, Punzi, Leonardo, Salvarani, Carlo, Galeazzi, Mauro, Angotti, Rossella, Messina, Mario, Tosi, Gian Marco, Rigante, Donato, and Cantarini, Luca

Subjects
Anakinra, Autoinflammatory disorders, Canakinumab, Interleukin-1, Safety profile, 0301 basic medicine, Male, Settore MED/16 - REUMATOLOGIA, 0302 clinical medicine, Retrospective Studie, Rheumatology, Child, Antibodies, Monoclonal, General Medicine, Middle Aged, Treatment Outcome, Autoinflammation, Female, Cohort study, medicine.drug, Human, Adult, medicine.medical_specialty, Adolescent, Logistic Model, Neutropenia, Antibodies, Monoclonal, Humanized, Autoimmune Disease, Autoimmune Diseases, 03 medical and health sciences, Young Adult, Internal medicine, Injection site reaction, medicine, Humans, Anakinra, Autoinflammatory disorders, Canakinumab, Interleukin-1, Safety profile, Adolescent, Adult, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Autoimmune Diseases, Child, Female, Humans, Interleukin 1 Receptor Antagonist Protein, Logistic Models, Male, Middle Aged, Retrospective Studies, Treatment Outcome, Young Adult, Adverse effect, Retrospective Studies, 030203 arthritis & rheumatology, business.industry, Retrospective cohort study, medicine.disease, Interleukin 1 Receptor Antagonist Protein, Logistic Models, 030104 developmental biology, Autoinflammatory disorder, Observational study, business
Abstract

A few studies have reported the safety profile of interleukin (IL)-1 blockers from real life. The aim of this study is to describe anakinra (ANA) and canakinumab (CAN) safety profile in children and adults, based on data from a real-life setting. Demographic, clinical, and therapeutic data from patients treated with ANA and CAN were retrospectively collected and analyzed. Four hundred and seventy five patients were enrolled; ANA and CAN were prescribed in 421 and 105 treatment courses, respectively. During a mean follow-up of 24.39 ± 27.04 months, 89 adverse events (AE) were recorded; 13 (14.61%) were classified as serious AE (sAE). The overall estimated rate of AE and sAE was 8.4 per 100 patients/year. Safety concerns were more frequent among patients aged ≥ 65 years compared with patients < 16 years (p = 0.002). No differences were detected in the frequency of safety concerns between monotherapy and combination therapy with immunosuppressants (p = 0.055), but a significant difference was observed when injection site reactions were excluded from AE (p = 0.01). No differences were identified in relation to gender (p = 0.462), different lines of biologic therapy (p = 0.775), and different dosages (p = 0.70 ANA; p = 0.39 CAN). The overall drug retention rate was significantly different according to the occurrence of safety concerns (p value < 0.0001); distinguishing between ANA and CAN, significance was maintained only for ANA (p < 0.0001 ANA; p > 0.05 CAN). Treatment duration was the only variable associated with onset of AE (OR = 0.399 [C.I. 0.250–0.638], p = 0.0001). ANA and CAN have shown an excellent safety profile; the risk for AE and sAE tends to decrease over time from the start of IL-1 inhibition.

Published
2018

218. NEW PERSPECTIVES IN DIAGNOSIS OF INTERSTITIAL LUNG DISEASE RELATED TO RHEUMATOID ARTHRITIS. VALIDATION STUDY OF AN ELECTRONIC STETHOSCOPE AND AD HOC SOFTWARE FOR DETECTION OF PULMONARY CRACKLES

Author

Manfredi, A, Sebastiani, M, Cassone, G, Fedele, A, Venerito, V, Trevisani, M, Furini, F, Addimanda, O, Gremese, E, Iannone, F, DELLA CASA, G, Cerri, S, Sandri, G, Pancaldi, F, Luppi, F, Ferri, C, MANFREDI, Andreina Teresa, SEBASTIANI, Marco, Cassone, Giulia, Fedele, A. L., Venerito, V., Trevisani, M., Furini, F., Addimanda, O., Gremese, E., Iannone, F., DELLA CASA, GIOVANNI, CERRI, Stefania, SANDRI, Gilda, PANCALDI, Fabrizio, LUPPI, Fabrizio, FERRI, Clodoveo, Manfredi, A, Sebastiani, M, Cassone, G, Fedele, A, Venerito, V, Trevisani, M, Furini, F, Addimanda, O, Gremese, E, Iannone, F, DELLA CASA, G, Cerri, S, Sandri, G, Pancaldi, F, Luppi, F, Ferri, C, MANFREDI, Andreina Teresa, SEBASTIANI, Marco, Cassone, Giulia, Fedele, A. L., Venerito, V., Trevisani, M., Furini, F., Addimanda, O., Gremese, E., Iannone, F., DELLA CASA, GIOVANNI, CERRI, Stefania, SANDRI, Gilda, PANCALDI, Fabrizio, LUPPI, Fabrizio, and FERRI, Clodoveo

Abstract

Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by synovial joint swelling and tenderness, secondary to the immune-system dysfunction, often complicated by extra-articular manifestations. Among them, lung involvement is very frequent and interstitial lung disease (ILD) represents one of the deleterious complications of RA with impact on both therapeutic approach and overall prognosis. Nevertheless, diagnosis of ILD often remains missing or delayed. Objectives: To preliminarily evaluate the predictive value of pulmonary sound recorded by an electronic stethoscope (ES) and elaborated by an ad hoc software in identification of RA-ILD diagnosed by mean of high resolution computed tomography (HRCT) in a multicenter study. Methods: RA patients who underwent HRCT in the last 12 months were enrolled. They were all auscultated with the ES (Littmann 3200TM 3M, USA), bilaterally, at dorsal level, in at least 3 pulmonary fields (medium and basal). All tracks recorded were analyzed by a suitably developed software capable of recognizing pathological crackles in lung sounds. Results were compared with radiologic findings detected in a blind manner by an expert radiologist. Results: One hundred and six RA patients were enrolled (M/F: 1/2.5, mean age 68.7±10.3); among them 45 (42.5%) showed ILD at HRCT. Three patients were excluded because of a low quality of the sound recorded. The algorithm showed a sensitivity and specificity of 72.1% and 84.4%, respectively and a positive/negative predictive value of 69.1% and 86.3%, respectively. Conclusions: Despite preliminary, these data suggest an important role of ES in clinical practice for an early diagnosis of ILD in RA patients and a significant reduction of inappropriate prescription of HRCT. Since very different types of ILD can occur in course of RA, with different radiologic features and localization, proper development of the measurement setup (ES and ad hoc software for the detection of PC)

Published
2017

219. Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group

Author

Cavagna, L, Nuno, L, Scire, C, Govoni, M, Longo, F, Franceschini, F, Neri, R, Castaneda, S, Sifuentes Giraldo, W, Caporali, R, Iannone, F, Fusaro, E, Paolazzi, G, Pellerito, R, Schwarting, A, Saketkoo, L, Ortego-Centeno, N, Quartuccio, L, Bartoloni, E, Specker, C, Pina Murcia, T, La Corte, R, Furini, F, Foschi, V, Bachiller Corral, J, Airo, P, Cavazzana, I, Martinez-Barrio, J, Hinojosa, M, Giannini, M, Barsotti, S, Menke, J, Triantafyllias, K, Vitetta, R, Russo, A, Bogliolo, L, Bajocchi, G, Bravi, E, Barausse, G, Bortolotti, R, Selmi, C, Parisi, S, Salaffi, F, Montecucco, C, Gonzalez-Gay, M, Cavagna L., Nuno L., Scire C. A., Govoni M., Longo F. J. L., Franceschini F., Neri R., Castaneda S., Sifuentes Giraldo W. A., Caporali R., Iannone F., Fusaro E., Paolazzi G., Pellerito R., Schwarting A., Saketkoo L. A., Ortego-Centeno N., Quartuccio L., Bartoloni E., Specker C., Pina Murcia T., La Corte R., Furini F., Foschi V., Bachiller Corral J., Airo P., Cavazzana I., Martinez-Barrio J., Hinojosa M., Giannini M., Barsotti S., Menke J., Triantafyllias K., Vitetta R., Russo A., Bogliolo L., Bajocchi G., Bravi E., Barausse G., Bortolotti R., Selmi C., Parisi S., Salaffi F., Montecucco C., Gonzalez-Gay M. A., Cavagna, L, Nuno, L, Scire, C, Govoni, M, Longo, F, Franceschini, F, Neri, R, Castaneda, S, Sifuentes Giraldo, W, Caporali, R, Iannone, F, Fusaro, E, Paolazzi, G, Pellerito, R, Schwarting, A, Saketkoo, L, Ortego-Centeno, N, Quartuccio, L, Bartoloni, E, Specker, C, Pina Murcia, T, La Corte, R, Furini, F, Foschi, V, Bachiller Corral, J, Airo, P, Cavazzana, I, Martinez-Barrio, J, Hinojosa, M, Giannini, M, Barsotti, S, Menke, J, Triantafyllias, K, Vitetta, R, Russo, A, Bogliolo, L, Bajocchi, G, Bravi, E, Barausse, G, Bortolotti, R, Selmi, C, Parisi, S, Salaffi, F, Montecucco, C, Gonzalez-Gay, M, Cavagna L., Nuno L., Scire C. A., Govoni M., Longo F. J. L., Franceschini F., Neri R., Castaneda S., Sifuentes Giraldo W. A., Caporali R., Iannone F., Fusaro E., Paolazzi G., Pellerito R., Schwarting A., Saketkoo L. A., Ortego-Centeno N., Quartuccio L., Bartoloni E., Specker C., Pina Murcia T., La Corte R., Furini F., Foschi V., Bachiller Corral J., Airo P., Cavazzana I., Martinez-Barrio J., Hinojosa M., Giannini M., Barsotti S., Menke J., Triantafyllias K., Vitetta R., Russo A., Bogliolo L., Bajocchi G., Bravi E., Barausse G., Bortolotti R., Selmi C., Parisi S., Salaffi F., Montecucco C., and Gonzalez-Gay M. A.

Abstract

Anti-Jo-1 is the most frequently detectable antibody in the antisynthetase syndrome (ASSD), an autoimmune disease characterized by the occurrence of arthritis, myositis, and interstitial lung disease (ILD). Recently, we organized an international collaborative group called American and European NEtwork of Antisynthetase Syndrome (AENEAS) for the study of this rare and fascinating disease. The group collected and published one of the largest series of ASSD patients ever described and with one of the longer follow-up ever reported. The number of participating centers is steadily increasing, as well as the available cohort. In the first paper, we showed that arthritis, myositis, and ILD may be frequently the only feature at disease onset, raising problems to reach a correct diagnosis of this syndrome. Nevertheless, we first observed that the ex novo appearance of further manifestations is common during the follow-up, strengthening the importance of a correct diagnosis. In our cohort, the 24 % of the 243 patients up to now collected had isolated arthritis as a presenting feature. These patients represent the most intriguing group in terms of differential diagnosis and clinical time course. Furthermore, data on this aspect are scanty, the reason that lead us to evaluate these aspects in our cohort of patients, reviewing also available literature. In fact, the most relevant aspect is that ASSD is rarely suspected in this setting of patients, in particular in case of poliarticular involvement, positive rheumatoid factor (RF), or anti-cyclic citrullinated peptide antibodies (ACPA) or evidence of joint erosions at plain radiographs. These findings were not rare in our cohort, and they have been also described in other series. Furthermore, manifestations such as Raynaud’s phenomenon, mechanic’s hands, and fever that may lead to the suspect of ASSD are observed only in a third of cases. If we consider the high rate of clinical picture progression in these patients, we fee

Published
2017

220. Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study

Author

Bartoloni, E, Gonzalez-Gay, M, Scire, C, Castaneda, S, Gerli, R, Lopez-Longo, F, Martinez-Barrio, J, Govoni, M, Furini, F, Pina, T, Iannone, F, Giannini, M, Nuno, L, Quartuccio, L, Ortego-Centeno, N, Alunno, A, Specker, C, Montecucco, C, Triantafyllias, K, Balduzzi, S, Sifuentes-Giraldo, W, Paolazzi, G, Bravi, E, Schwarting, A, Pellerito, R, Russo, A, Selmi, C, Saketkoo, L, Fusaro, E, Parisi, S, Pipitone, N, Franceschini, F, Cavazzana, I, Neri, R, Barsotti, S, Codullo, V, Cavagna, L, Bartoloni E., Gonzalez-Gay M. A., Scire CA., Castaneda S., Gerli R., Lopez-Longo F. J., Martinez-Barrio J., Govoni M., Furini F., Pina T., Iannone F., Giannini M., Nuno L., Quartuccio L., Ortego-Centeno N., Alunno A., Specker C., Montecucco C., Triantafyllias K., Balduzzi S., Sifuentes-Giraldo W. A., Paolazzi G., Bravi E., Schwarting A., Pellerito R., Russo A., Selmi C., Saketkoo L. -A., Fusaro E., Parisi S., Pipitone N., Franceschini F., Cavazzana I., Neri R., Barsotti S., Codullo V., Cavagna L., Bartoloni, E, Gonzalez-Gay, M, Scire, C, Castaneda, S, Gerli, R, Lopez-Longo, F, Martinez-Barrio, J, Govoni, M, Furini, F, Pina, T, Iannone, F, Giannini, M, Nuno, L, Quartuccio, L, Ortego-Centeno, N, Alunno, A, Specker, C, Montecucco, C, Triantafyllias, K, Balduzzi, S, Sifuentes-Giraldo, W, Paolazzi, G, Bravi, E, Schwarting, A, Pellerito, R, Russo, A, Selmi, C, Saketkoo, L, Fusaro, E, Parisi, S, Pipitone, N, Franceschini, F, Cavazzana, I, Neri, R, Barsotti, S, Codullo, V, Cavagna, L, Bartoloni E., Gonzalez-Gay M. A., Scire CA., Castaneda S., Gerli R., Lopez-Longo F. J., Martinez-Barrio J., Govoni M., Furini F., Pina T., Iannone F., Giannini M., Nuno L., Quartuccio L., Ortego-Centeno N., Alunno A., Specker C., Montecucco C., Triantafyllias K., Balduzzi S., Sifuentes-Giraldo W. A., Paolazzi G., Bravi E., Schwarting A., Pellerito R., Russo A., Selmi C., Saketkoo L. -A., Fusaro E., Parisi S., Pipitone N., Franceschini F., Cavazzana I., Neri R., Barsotti S., Codullo V., and Cavagna L.

Abstract

Objective Arthritis, myositis and interstitial lung disease (ILD) constitute the classic clinical triad of anti-synthetase syndrome (ASSD). These patients experience other accompanying features, such as Raynaud's phenomenon, fever or mechanic's hands. Most ASSD patients develop the complete triad during the follow-up. In the present study we aimed to determine whether the subsequent appearance of accompanying features may suggest the development of triad findings lacking at the onset in anti-Jo1 positive ASSD patients. Methods Anti-Jo1 positive patients presenting with incomplete ASSD (no > 2 classic triad features) were assessed. Clinical characteristics and clusters of disease manifestations were retrospectively collected and analyzed in a large international multicenter cohort of ASSD patients. Results 165 patients (123 women) with incomplete ASSD were identified. Ninety-five patients (57.5%) developed new classic triad manifestations after 15 months median (IQR 9–51) and 40 (24%) developed new accompanying features after 19 months median (IQR 6–56) from disease onset. During the follow-up, the ex-novo occurrence of triad features was observed in 32 out of 40 patients (80%) with new accompanying findings and in 63 out of 125 patients (50.5%) without new accompanying findings (p = 0.002). In patients with at least one new accompanying feature the odds ratio for the occurrence of new triad manifestations was 3.94 with respect to patients not developing ex-novo accompanying findings (95% CI 1.68–9.21, p = 0.002). Conclusion Anti-Jo1 ASSD patients with incomplete forms at disease onset are at high risk for the subsequent occurrence of lacking classic triad findings. Although all ASSD patients should be carefully assessed for the occurrence of new triad features, a closer follow-up should be considered in the subgroup of patients developing ex novo accompanying findings. These patients, indeed, have near four-fold increased risk f

Published
2017

226. Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort

Author

Mihai, Carina, Distler, Oliver, Gheorghiu, Ana Maria, Constantin, Paul I, Dobrota, Rucsandra, Jordan, Suzana, Smith, Vanessa, Hachulla, Eric, Henes, Jörg, Siegert, Elise, Vettori, Serena, Müller-Ladner, Ulf, Matucci Cerinic, Marco, Allanore, Yannick, Lepri, G, Jaeger, Vk, Walker, Ua, Iannone, F, Cacciapaglia, F, Tomčík, M, Becvar, R, Rednic, S, Petcu, A, Szabo, I, Codullo, V, Caporali, R, Montecucco, C, Carreira, P, Ioven, B, Minier, T, Czirják, L, Chizzolini, C, Allali, D, Zanatta, E, Doria, A, Gabrielli, A, Airò, P, Lazzaroni, Mg, Radić, M, Martinovic, D, Braun-Moscovici, Y, Balbir-Gurman, A, Hunzelmann, N, Caramaschi, P, Morovic-Vergles, J, Denton, C, Santamaria, V, Heitmann, S, Krasowska, D, Michalska-Jakubus, M, Seidel, M, Foeldvari, I, Helmus, N, Salvador, M, Stamenkovic, B, Stankovic, A, Ananieva, L, Herrick, A, Engelhart, M, De La Puente, C, Hoffmann-Vold, Am, Midtvedt, Ø, Launay, D, Sobanski, V, Riccieri, V, Opris-Belinski, D, Groseanu, L, Ionescu, R, Bojinca, M, Sunderkötter, C, Distler, J, Ingegnoli, F, van der Haecke, A, Ullman, S, Pozzi, Mr, Eyerich, K, Vanthuyne, M, Erler, A, Aringer, M, De Langhe, E, Baresic, M, Mayer, M, Anic, B, Yavuz, S, Granel, B, Popa, S, Agachi, S, Zenone, T, Mathieu, A, Vacca, A, Solanki, K, Veale, D, Loyo, E, Tineo, C, Gigante, A, Rosato, E, Oksel, F, Yagurcu, F, Tănăseanu, Cm, Visalli, E, Benenati, A, Foti, R, Ancuta, C, Dan, D, Adler, S, Villiger, P, Fathi, N, de la Peña Lefebvre PG, González Martín, J, Chatelus, E, Sibilia, J, Litinsky, I, Del Galdo, F, Ann Sakettkoo, L, Kerzberg, E, Bianchi, Wa, Bianchi, Bv, Castellví, I, Limonta, M, Rimar, D, Couto, M, Ribi, C, Spertini, F, Kahl, S, Hsu, V, Poindron, V, Meghit, K, Martin, T, Kolstad, K, Chung, L, Thiele, A, Schmeiser, T, Zdrojewski, Z, Riemekasten, G, Levy, Y, Cardoneanu, A, Burlui, A, Rezus, E, Pamuk, On, Talotta, R, Bongiovanni, S, Puttini, Ps., Mihai, Carina, Distler, Oliver, Gheorghiu, Ana Maria, Constantin, Paul I, Dobrota, Rucsandra, Jordan, Suzana, Smith, Vanessa, Hachulla, Eric, Henes, Jörg, Siegert, Elise, Vettori, Serena, Müller-Ladner, Ulf, Matucci Cerinic, Marco, Allanore, Yannick, Giovanna, Cuomo, Chizzolini, Carlo, Allali, Danièle, and University of Zurich

Subjects
Adult, Male, medicine.medical_specialty, Databases, Factual, systemic sclerosis, digital ulcer, 610 Medicine & health, Disease, ddc:616.07, Logistic regression, Systemic scleroderma, Cohort Studies, Rheumatology, Risk Factors, Internal medicine, Cox proportional hazards regression, medicine, Humans, Pharmacology (medical), In patient, digital ulcers, gangrene, vasculopathy, Aged, Gangrene, Scleroderma, Systemic, business.industry, Incidence (epidemiology), Incidence, 10051 Rheumatology Clinic and Institute of Physical Medicine, food and beverages, Middle Aged, medicine.disease, Cross-Sectional Studies, Cohort, Female, business, systemic sclerosi
Abstract

Objective In patients with SSc, peripheral vasculopathy can promote critical ischaemia and gangrene. The aim of this study was to investigate the prevalence, incidence and risk factors for gangrene in the EUSTAR cohort. Methods We included patients from the EUSTAR database fulfilling the ACR 1980 or the ACR/EULAR 2013 classification criteria for SSc, with at least one visit recording data on gangrene. Centres were asked for supplementary data on traditional cardiovascular risk factors. We analysed the cross-sectional relationship between gangrene and its potential risk factors by univariable and multivariable logistic regression. Longitudinal data were analysed by Cox proportional hazards regression. Results 1757 patients were analysed (age 55.9 [14.5] years, disease duration 7.9 [10.3] years, male sex 16.7%, 24.6% diffuse cutaneous subset [dcSSc]). At inclusion, 8.9% of patients had current or previous digital gangrene, 16.1% had current digital ulcers (DUs) and 42.7% had ever had DUs (current or previous). Older age, DUs ever and dcSSc were statistically significant risk factors for gangrene in the cross-sectional multivariable model. During a median follow-up of 13.1 months, 16/771 (0.9%) patients developed gangrene. All 16 patients who developed gangrene had previously had DUs and gangrene. Further risk factors for incident gangrene were the dcSSc subset and longer disease duration. Conclusion In unselected SSc patients, gangrene occurs in about 9% of SSc patients. DUs ever and, to a lesser extent, the dcSSc subset are strongly and independently associated with gangrene, while traditional cardiovascular risk factors could not be identified as risk factors.

Published
2019

227. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis and panuveitis: a retrospective observational study of 107 patients

Author

Fabiani, C, Vitale, A, Rigante, Donato, Emmi, G, Bitossi, A, Lopalco, G, Sota, J, Guerriero, S, Orlando, I, Capozzoli, M, Gentileschi, S, Iannone, F, Frediani, B, Galeazzi, M, Vannozzi, L, Tosi, Gm, and Cantarini, L

Subjects
Adult, Male, medicine.medical_specialty, Settore MED/16 - REUMATOLOGIA, TNF-blocking antibodies, Behcet's disease, Uveitis, 03 medical and health sciences, Behçet’s disease, Macular edema, Retinal vasculitis, Rheumatology, 0302 clinical medicine, Internal medicine, Adalimumab, Humans, Medicine, 030212 general & internal medicine, Retrospective Studies, 030203 arthritis & rheumatology, Tumor Necrosis Factor-alpha, business.industry, Behcet Syndrome, Uveitis, Posterior, Retrospective cohort study, General Medicine, Middle Aged, medicine.disease, Infliximab, Treatment Outcome, Intermediate uveitis, Female, business, Uveitis, Intermediate, medicine.drug
Abstract

To compare the efficacy of adalimumab (ADA) and infliximab (IFX) in patients with non-infectious intermediate uveitis, posterior uveitis, and panuveitis. Demographic, clinical, instrumental, and therapeutic data from patients enrolled were collected at the start of treatment, at 12-month follow-up, and at the last follow-up assessment. One hundred seven patients (46 females, 187 eyes) were enrolled, 66 (61.7%) treated with ADA and 41 (38.3%) with IFX. Bilateral involvement was observed in 80 cases. The mean follow-up was 26.45 ± 21.71 months for ADA patients and 56.60 ± 56.04 months for IFX patients. The overall decrease of uveitis frequency during the first 12 months of treatment was 66.7% in the IFX group and 84.2% in the ADA group, compared to the previous 12 months (p = 0.09). A significantly higher corticosteroid dosage was found among patients treated with ADA at the last follow-up visit (p = 0.008). The percentage of patients co-administered with corticosteroids was significantly higher among ADA patients both at the 12-month visit (p = 0.03) and at the last visit (p = 0.0004). The frequency of uveitic macular edema (UME) was significantly higher among patients treated with ADA compared to those treated with IFX at the 12-month assessment (p = 0.015) and at the last follow-up visit (p = 0.011); central macular thickness was significantly higher in ADA group compared to the IFX group at the last follow-up assessment (p = 0.04). ADA and IFX have shown a similar efficacy in controlling uveitis relapses, but IFX showed a more pronounced corticosteroid sparing effect and a significantly higher capacity in resolving UME compared to ADA.

Published
2019

230. Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients

Author

Favalli, E. G., Conti, F., Selmi, C., Iannone, F., Bucci, R., D Onofrio, F., Carlino, G., Santo, L., Semeraro, A., Zuccaro, C., D Angelo, S., Atzeni, F., Marino, F., Monti, S., Guidelli, G. M., Francesca Romana Spinelli, Biggioggero, M., and Caporali, R.

Subjects
psoriatic arthritis, Treatment Outcome, Italy, Antirheumatic Agents, Anti-Inflammatory Agents, Non-Steroidal, Arthritis, Psoriatic, Humans, effectiveness, Female, apemilast, Retrospective Studies, Thalidomide
Abstract

We aimed to evaluate the baseline characteristics, the reasons for prescription, and the effectiveness/safety profile of real-life apremilast for the treatment of psoriatic arthritis (PsA).PsA patients treated with apremilast were retrospectively extracted from an Italian multicentric cohort. Baseline population characteristics and reasons for apremilast prescription were analysed. Clinical response was defined as the proportion of patients achieving Disease Activity in PSoriatic Arthritis (DAPSA) remission/low disease activity (LDA), minimal disease activity (MDA), and very low disease activity (VLDA). Six-month retention rate was computed by the Kaplan-Meier method, with a detailed analysis of reasons for discontinuation. Univariate and multivariate models were developed to examine predictors of clinical response and persistence.The study population included 131 patients mainly with oligoarticular PsA (58%), carrying at least one comorbidity (64.1%, in particular history of malignancies [25.9%] and latent tuberculosis [16.3%]) treated with apremilast as first-line targeted therapy (47.7%) or in biologics failures (52.3%). Contraindication to biologics (60.3%) and lack of poor prognostic factors (27.5%) were the most frequent reason for apremilast prescription. The 6-month retention rate was 72.1%. Inefficacy (n=7), diarrhoea (n=10), nausea (n=3), and headache (n=7) were the most frequent reasons for discontinuation. At 3 months DAPSA LDA/remission, MDA, and VLDA were observed in 40.3, 6.7, and 5.6% of patients, respectively. Female sex was a negative predictor of both retention rate and clinical response.In our real-life analysis apremilast was mainly used in oligoarticular PsA carrying comorbidities leading to contraindications to biologics. Effectiveness and safety profiles were consistent with clinical trials.

Published
2019

232. Efficacy of anti-tumour necrosis factor-α monoclonal antibodies in patients with non-infectious anterior uveitis

Author

Fabiani, C., Vitale, A., Rigante, D., Giacomo Emmi, Lopalco, G., Sota, J., Vannozzi, L., Guerriero, S., Bitossi, A., Orlando, I., Franceschini, R., Frediani, B., Galeazzi, M., Iannone, F., Tosi, G. M., and Cantarini, L.

Subjects
Male, Treatment Outcome, Tumor Necrosis Factor-alpha, Antirheumatic Agents, Adalimumab, Antibodies, Monoclonal, Humans, Female, Symptom Flare Up, Uveitis, Anterior, Infliximab, Retrospective Studies
Abstract

To assess the efficacy of monoclonal anti-tumour necrosis factor (TNF)-α agents in patients with anterior uveitis (AU) in terms of decrease of recurrences, variation of visual acuity and steroid sparing effect and to identify any demographic, clinical or therapeutic variables associated with a sustained response to monoclonal TNF-α inhibitors.Data from patients suffering from AU treated with adalimumab, infliximab, golimumab or certolizumab pegol were retrospectively collected and statistically analysed.Sixty-nine patients (22 males, 47 females), corresponding to 101 eyes, were enrolled. The mean follow-up period was 29.25±23.51 months. The rate of ocular flares decreased from 42.03 events/100 patients/year recorded during the 12 months preceding the start of TNF-α inhibitors to 2.9 flares/100 patients/year after the start of treatment (p0.0001). The overall decrease in ocular flares was 93.1%. No statistically significant changes were identified in the best corrected visual acuity during the follow-up period (p0.99). The number of patients treated with corticosteroids at baseline was significantly higher compared with that referred to the 12-month evaluation (p0.001) and to the last follow-up visit (p=0.006). Concomitant treatment with conventional disease-modifying anti-rheumatic drugs (cDMARDs) represented the sole clinical, demographic or therapeutic variable associated with long-term treatment duration (p=0.045, R2=0.87).Monoclonal TNF-α inhibitors induce a remarkable decrease in the recurrence of AU during a long-term follow-up period and lead to a significant steroid sparing effect along with stabilisation of visual acuity. Concomitant treatment with cDMARDs represented the sole variable associated with treatment duration in the long-term.

Published
2019

233. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study

Author

Elhai, M, Boubaya, M, Distler, O, Smith, V, Matucci-Cerinic, M, Sancho, JJ, Truchetet, ME, Braun-Moscovici, Y, Iannone, F, Novikov, PI, Lescoat, A, Siegert, E, Castellvi, I, Airo, P, Vettori, S, Langhe, E, Hachulla, E, Erler, A, Ananieva, L, Krusche, M, Lopez-Longo, FJ, Distler, JHW, Hunzelmann, N, Hoffmann-Vold, AM, Riccieri, V, Hsu, VM, Pozzi, MR, Ancuta, C, Rosato, E, Mihai, C, Kuwana, M, Saketkoo, LA, Chizzolini, C, Hesselstrand, R, Ullman, S, Yavuz, S, Rednic, S, Caimmi, C, Bloch-Queyrat, C, Allanore, Y, Guiducci, S, Walker, UA, Kyburz, D, Lapadula, G, Maurer, B, Jordan, S, Dobrota, R, Becvar, R, Sierakowsky, S, Bielecka, OK, Sulli, A, Cutolo, M, Cuomo, G, Nicoara, I, Kahan, A, Vlachoyiannopoulos, PG, Montecucco, CM, Caporali, R, Stork, J, Inanc, M, Carreira, PE, Novak, S, Czirjak, L, Varju, C, Kucharz, EJ, Kotulska, A, Kopec-Medrek, M, Widuchowska, M, Cozzi, F, Rozman, B, Mallia, C, Coleiro, B, Gabrielli, A, Farge, D, Wu, C, Marjanovic, Z, Faivre, H, Hij, D, Dhamadi, R, Wollheim, F, Scheja, A, Wuttge, DM, Andreasson, K, Martinovic, D, Balbir-Gurman, A, Trotta, F, Lo Monaco, A, Pellerito, R, Mauriziano, O, Caramaschi, P, Morovic-Vergles, J, Black, C, Denton, C, Damjanov, N, Henes, J, Santamaria, VO, Heitmann, S, Krasowska, D, Matthias, Hasler, P, Burkhardt, H, Himsel, A, Bajocchi, G, Da Silva, JAP, Salvador, MJ, Stamenkovic, B, Stankovic, A, Selmi, CF, De Santis, M, Tikly, M, Denisov, LN, Herrick, A, Muller-Ladner, U, Frerix, M, Tarner, I, Scorza, R, Puppo, F, Engelhart, M, Strauss, G, Nielsen, H, Damgaard, K, Szucs, G, Mendoza, AZ, de la Puente, C, Giraldo, WAS, Midtvedt, O, Reiseter, S, Garen, T, Launay, D, Valesini, G, Ionescu, RM, Groseanu, L, Opris, D, Cornateanu, RS, Ionitescu, R, Gherghe, AM, Soare, A, Gorga, M, Bojinca, M, Milicescu, M, Sunderkotter, C, Kuhn, A, Sandorfi, N, Schett, G, Beyer, C, Meroni, P, Ingegnoli, F, Mouthon, L, De Keyser, F, Melsens, K, Cantatore, FP, Corrado, A, Iversen, L, von Muhlen, CA, Bohn, JM, Lonzetti, LS, Eyerich, K, Hein, R, Knott, E, Wiland, P, Szmyrka-Kaczmarek, M, Sokolik, R, Morgiel, E, Madej, M, Houssiau, FA, Krummel-Lorenz, B, Saar, P, Aringer, M, Gunther, C, Westhovens, R, Lenaerts, J, Anic, B, Baresic, M, Mayer, M, Uprus, M, Otsa, K, Granel, B, Muller, CD, Radominski, SC, Azevedo, VF, Jimenez, S, Busquets, J, Agachi, S, Groppa, L, Chiaburu, L, Russu, E, Popa, S, Zenone, T, Pileckyte, M, Mathieu, A, Vacca, A, Sampaio-Barros, PD, Yoshinari, NH, Marangoni, RG, Martin, P, Fuocco, L, Stebbings, S, Highton, J, Chapman, P, O'Donnell, J, Stamp, L, Doube, A, Solanki, K, Veale, D, O'Rourke, M, Loyo, E, Li, MT, Mohamed, WAAA, Amoroso, A, Gigante, A, Oksel, F, Yargucu, F, Tanaseanu, CM, Popescu, M, Dumitrascu, A, Tiglea, I, Foti, R, Chirieac, R, Furst, D, Villiger, P, Adler, S, van Laar, J, Kayser, C, Fathi, N, Hassanien, M, Lefebvre, PGD, Rubio, SR, Exposito, MV, Chatelus, E, Sibilia, J, Gottenberg, JE, Chifflot, H, Litinsky, I, Emery, P, Buch, M, Del Galdo, F, Venalis, A, Butrimiene, I, Venalis, P, Rugiene, R, Karpec, D, Lasky, JA, Cosentino, V, Kerzberg, E, Montoya, F, Bianchi, W, Carneiro, S, Maretti, GB, Bianchi, DV, Limonta, M, Lupi, ALBE, Lupi, E, Rosner, I, Rozenbaum, M, Slobodin, G, Boulman, N, Rimar, D, Couto, M, Kahl, S, Chen, F, McCloskey, D, Malveaux, H, Spertini, F, Ribi, C, Buss, G, Martin, T, Guffroy, A, Poindron, V, Chotchaeva, F, Mukhin, NA, Moiseev, S, EUSTAR Network, Elhai, Muriel, Boubaya, Marouane, Distler, Oliver, Smith, Vanessa, Matucci-Cerinic, Marco, Alegre Sancho, Juan José, Truchetet, Marie-Elise, Braun-Moscovici, Yolanda, Iannone, Florenzo, Novikov, Pavel I, Lescoat, Alain, Siegert, Elise, Castellví, Ivan, Airó, Paolo, Vettori, Serena, De Langhe, Ellen, Hachulla, Eric, Erler, Anne, Ananieva, Lidia, Krusche, Martin, López-Longo, F. J., Distler, Jörg H W, Hunzelmann, Nicola, Hoffmann-Vold, Anna-Maria, Riccieri, Valeria, Hsu, Vivien M, Pozzi, Maria R, Ancuta, Codrina, Rosato, Edoardo, Mihai, Carina, Kuwana, Masataka, Saketkoo, Lesley Ann, Chizzolini, Carlo, Hesselstrand, Roger, Ullman, Susanne, Yavuz, Sule, Rednic, Simona, Caimmi, Cristian, Bloch-Queyrat, Coralie, Allanore, Yannick, and Cuomo, Giovanna

Subjects
Male, Vital capacity, systemic sclerosis, Pulmonary Fibrosis, Vital Capacity, Scleroderma, lung fibrosis, rituximab, skin fibrosis, immune system diseases, DLCO, hemic and lymphatic diseases, Immunology and Allergy, Medicine, Prospective Studies, Registries, skin and connective tissue diseases, Prospective cohort study, Lung, skin fibrosi, Skin, ddc:616, integumentary system, Orvostudományok, Middle Aged, Respiratory Function Tests, lung fibrosis, rituximab, skin fibrosis, systemic sclerosis, Treatment Outcome, lung fibrosi, Antirheumatic Agents, Systemic sclerosis, Rituximab, Female, systemic sclerosi, medicine.drug, Adult, medicine.medical_specialty, Immunology, Klinikai orvostudományok, General Biochemistry, Genetics and Molecular Biology, FEV1/FVC ratio, Rheumatology, Internal medicine, Humans, Adverse effect, Propensity Score, Aged, Biochemistry, Genetics and Molecular Biology (all), Scleroderma, Systemic, Skin fibrosis, business.industry, medicine.disease, Fibrosis, Lung fibrosis, business
Abstract

ObjectiveTo assess the safety and efficacy of rituximab in systemic sclerosis (SSc) in clinical practice.MethodsWe performed a prospective study including patients with SSc from the European Scleroderma Trials and Research (EUSTAR) network treated with rituximab and matched with untreated patients with SSc. The main outcomes measures were adverse events, skin fibrosis improvement, lung fibrosis worsening and steroids use among propensity score-matched patients treated or not with rituximab.Results254 patients were treated with rituximab, in 58% for lung and in 32% for skin involvement. After a median follow-up of 2 years, about 70% of the patients had no side effect. Comparison of treated patients with 9575 propensity-score matched patients showed that patients treated with rituximab were more likely to have skin fibrosis improvement (22.7 vs 14.03 events per 100 person-years; OR: 2.79 [1.47–5.32]; p=0.002). Treated patients did not have significantly different rates of decrease in forced vital capacity (FVC)>10% (OR: 1.03 [0.55–1.94]; p=0.93) nor in carbon monoxide diffusing capacity (DLCO) decrease. Patients having received rituximab were more prone to stop or decrease steroids (OR: 2.34 [1.56–3.53], pConclusionRituximab use was associated with a good safety profile in this large SSc-cohort. Significant change was observed on skin fibrosis, but not on lung. However, the limitation is the observational design. The potential stabilisation of lung fibrosis by rituximab has to be addressed by a randomised trial.

Published
2019

234. Predictors of DAPSA28 Remission at 6 Months in Bio-Naive Patients with Psoriatic Arthritis Starting a TNF Inhibitor in Clinical Practice-Results from the EuroSpA Collaboration

Author

Ornbjerg, Lm, Georgiadis, S, Jacobsson, L, Loft, Ag, Iannone, F, Moeller, B, Sexton, J, Mann, H, Santos, Mj, Pombo-Suarez, M, Eklund, Kk, Tomsic, M, Gudbjornsson, B, Erten, S, Codreanu, C, van der Horst-Bruinsma, I, Wallman, J, Sebastiani, M, Nissen, Mj, Kristianslund, E, Pavelka, K, Vieira-Sousa, E, Sanchez-Piedra, C, Trokovic, N, Rotar, Z, Love, Tj, Yolbas, S, Ionescu, R, van de Sande, M, Jones, G, Michelsen, B, Ostergaard, M, and Hetland, Ml

Published
2019

235. Monte Carlo techniques to analyse the electrical mismatch losses in large-scale photovoltaic generators

Author

Iannone, F., Noviello, G., and Sarno, A.

Subjects
Monte Carlo method -- Usage, Photovoltaic power generation -- Research, Earth sciences, Petroleum, energy and mining industries
Abstract

In large-scale photovoltaic generators, the arrangement of modules with different electrical characteristics could involve a considerable mismatch between the single components resulting in a power loss. This means the actual power is less than the sum of the maximum output powers of the individual PV modules, operating at same irradiance-temperature conditions. To reduce the mismatch losses and to calculate it under operating conditions, a statistical approach based on Monte Carlo simulation techniques, has been developed and validated. The simulation model shows that it is possible to meet the required mismatch level, with a random arrangement, starting from a modules population characterized in terms of short circuit current, [I.sub.sc] and open circuit voltage [V.sub.oc], by a probability density function with a imposed variance. The method has been successfully applied for a 100 kWp standard unit photovoltaic generator, the computational results have shown good agreement with the experimental data.

Published
1998

241. Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course

Author

Cavagna, L, Trallero-Araguás, E, Meloni, F, Cavazzana, I, Rojas-Serrano, J, Feist, E, Zanframundo, G, Morandi, V, Meyer, A, Pereira da Silva, J, Matos Costa, C, Molberg, O, Andersson, H, Codullo, V, Mosca, M, Barsotti, S, Neri, R, Scirè, C, Govoni, M, Furini, F, Lopez-Longo, F, Martinez-Barrio, J, Schneider, U, Lorenz, H, Doria, A, Ghirardello, A, Ortego-Centeno, N, Confalonieri, M, Tomietto, P, Pipitone, N, Rodriguez Cambron, A, Blázquez Cañamero, M, Voll, R, Wendel, S, Scarpato, S, Maurier, F, Limonta, M, Colombelli, P, Giannini, M, Geny, B, Arrigoni, E, Bravi, E, Migliorini, P, Mathieu, A, Piga, M, Drott, U, Delbrueck, C, Bauhammer, J, Cagnotto, G, Vancheri, C, Sambataro, G, De Langhe, E, Sainaghi, P, Monti, C, Gigli Berzolari, F, Romano, M, Bonella, F, Specker, C, Schwarting, A, Villa Blanco, I, Selmi, C, Ceribelli, A, Nuno, L, Mera-Varela, A, Perez Gomez, N, Fusaro, E, Parisi, S, Sinigaglia, L, Del Papa, N, Benucci, M, Cimmino, M, Riccieri, V, Conti, F, Sebastiani, G, Iuliano, A, Emmi, G, Cammelli, D, Sebastiani, M, Manfredi, A, Bachiller-Corral, J, Sifuentes Giraldo, W, Paolazzi, G, Saketkoo, L, Giorgi, R, Salaffi, F, Cifrian, J, Caporali, R, Locatelli, F, Marchioni, E, Pesci, A, Dei, G, Pozzi, M, Claudia, L, Distler, J, Knitza, J, Schett, G, Iannone, F, Fornaro, M, Franceschini, F, Quartuccio, L, Gerli, R, Bartoloni, E, Bellando Randone, S, Zampogna, G, Gonzalez Perez, M, Mejia, M, Vicente, E, Triantafyllias, K, Lopez-Mejias, R, Matucci-Cerinic, M, Selva-O'Callaghan, A, Castañeda, S, Montecucco, C, Gonzalez-Gay, M, Cavagna, Lorenzo, Trallero-Araguás, Ernesto, Meloni, Federica, Cavazzana, Ilaria, Rojas-Serrano, Jorge, Feist, Eugen, Zanframundo, Giovanni, Morandi, Valentina, Meyer, Alain, Pereira da Silva, Jose Antonio, Matos Costa, Carlo Jorge, Molberg, Oyvind, Andersson, Helena, Codullo, Veronica, Mosca, Marta, Barsotti, Simone, Neri, Rossella, Scirè, Carlo, Govoni, Marcello, Furini, Federica, Lopez-Longo, Francisco Javier, Martinez-Barrio, Julia, Schneider, Udo, Lorenz, Hanns-Martin, Doria, Andrea, Ghirardello, Anna, Ortego-Centeno, Norberto, Confalonieri, Marco, Tomietto, Paola, Pipitone, Nicolò, Rodriguez Cambron, Ana Belen, Blázquez Cañamero, María Ángeles, Voll, Reinhard Edmund, Wendel, Sarah, Scarpato, Salvatore, Maurier, Francois, Limonta, Massimiliano, Colombelli, Paolo, Giannini, Margherita, Geny, Bernard, Arrigoni, Eugenio, Bravi, Elena, Migliorini, Paola, Mathieu, Alessandro, Piga, Matteo, Drott, Ulrich, Delbrueck, Christiane, Bauhammer, Jutta, Cagnotto, Giovanni, Vancheri, Carlo, Sambataro, Gianluca, De Langhe, Ellen, Sainaghi, Pier Paolo, Monti, Cristina, Gigli Berzolari, Francesca, Romano, Mariaeva, Bonella, Francesco, Specker, Christof, Schwarting, Andreas, Villa Blanco, Ignacio, Selmi, Carlo, Ceribelli, Angela, Nuno, Laura, Mera-Varela, Antonio, Perez Gomez, Nair, Fusaro, Enrico, Parisi, Simone, Sinigaglia, Luigi, Del Papa, Nicoletta, Benucci, Maurizio, Cimmino, Marco Amedeo, Riccieri, Valeria, Conti, Fabrizio, Sebastiani, Gian Domenico, Iuliano, Annamaria, Emmi, Giacomo, Cammelli, Daniele, Sebastiani, Marco, Manfredi, Andreina, Bachiller-Corral, Javier, Sifuentes Giraldo, Walter Alberto, Paolazzi, Giuseppe, Saketkoo, Lesley Ann, Giorgi, Roberto, Salaffi, Fausto, Cifrian, Jose, Caporali, Roberto, Locatelli, Francesco, Marchioni, Enrico, Pesci, Alberto, Dei, Giulia, Pozzi, Maria Rosa, Claudia, Lomater, Distler, Jorg, Knitza, Johannes, Schett, George, Iannone, Florenzo, Fornaro, Marco, Franceschini, Franco, Quartuccio, Luca, Gerli, Roberto, Bartoloni, Elena, Bellando Randone, Silvia, Zampogna, Giuseppe, Gonzalez Perez, Montserrat I, Mejia, Mayra, Vicente, Esther, Triantafyllias, Konstantinos, Lopez-Mejias, Raquel, Matucci-Cerinic, Marco, Selva-O'Callaghan, Albert, Castañeda, Santos, Montecucco, Carlomaurizio, Gonzalez-Gay, Miguel Angel, Cavagna, L, Trallero-Araguás, E, Meloni, F, Cavazzana, I, Rojas-Serrano, J, Feist, E, Zanframundo, G, Morandi, V, Meyer, A, Pereira da Silva, J, Matos Costa, C, Molberg, O, Andersson, H, Codullo, V, Mosca, M, Barsotti, S, Neri, R, Scirè, C, Govoni, M, Furini, F, Lopez-Longo, F, Martinez-Barrio, J, Schneider, U, Lorenz, H, Doria, A, Ghirardello, A, Ortego-Centeno, N, Confalonieri, M, Tomietto, P, Pipitone, N, Rodriguez Cambron, A, Blázquez Cañamero, M, Voll, R, Wendel, S, Scarpato, S, Maurier, F, Limonta, M, Colombelli, P, Giannini, M, Geny, B, Arrigoni, E, Bravi, E, Migliorini, P, Mathieu, A, Piga, M, Drott, U, Delbrueck, C, Bauhammer, J, Cagnotto, G, Vancheri, C, Sambataro, G, De Langhe, E, Sainaghi, P, Monti, C, Gigli Berzolari, F, Romano, M, Bonella, F, Specker, C, Schwarting, A, Villa Blanco, I, Selmi, C, Ceribelli, A, Nuno, L, Mera-Varela, A, Perez Gomez, N, Fusaro, E, Parisi, S, Sinigaglia, L, Del Papa, N, Benucci, M, Cimmino, M, Riccieri, V, Conti, F, Sebastiani, G, Iuliano, A, Emmi, G, Cammelli, D, Sebastiani, M, Manfredi, A, Bachiller-Corral, J, Sifuentes Giraldo, W, Paolazzi, G, Saketkoo, L, Giorgi, R, Salaffi, F, Cifrian, J, Caporali, R, Locatelli, F, Marchioni, E, Pesci, A, Dei, G, Pozzi, M, Claudia, L, Distler, J, Knitza, J, Schett, G, Iannone, F, Fornaro, M, Franceschini, F, Quartuccio, L, Gerli, R, Bartoloni, E, Bellando Randone, S, Zampogna, G, Gonzalez Perez, M, Mejia, M, Vicente, E, Triantafyllias, K, Lopez-Mejias, R, Matucci-Cerinic, M, Selva-O'Callaghan, A, Castañeda, S, Montecucco, C, Gonzalez-Gay, M, Cavagna, Lorenzo, Trallero-Araguás, Ernesto, Meloni, Federica, Cavazzana, Ilaria, Rojas-Serrano, Jorge, Feist, Eugen, Zanframundo, Giovanni, Morandi, Valentina, Meyer, Alain, Pereira da Silva, Jose Antonio, Matos Costa, Carlo Jorge, Molberg, Oyvind, Andersson, Helena, Codullo, Veronica, Mosca, Marta, Barsotti, Simone, Neri, Rossella, Scirè, Carlo, Govoni, Marcello, Furini, Federica, Lopez-Longo, Francisco Javier, Martinez-Barrio, Julia, Schneider, Udo, Lorenz, Hanns-Martin, Doria, Andrea, Ghirardello, Anna, Ortego-Centeno, Norberto, Confalonieri, Marco, Tomietto, Paola, Pipitone, Nicolò, Rodriguez Cambron, Ana Belen, Blázquez Cañamero, María Ángeles, Voll, Reinhard Edmund, Wendel, Sarah, Scarpato, Salvatore, Maurier, Francois, Limonta, Massimiliano, Colombelli, Paolo, Giannini, Margherita, Geny, Bernard, Arrigoni, Eugenio, Bravi, Elena, Migliorini, Paola, Mathieu, Alessandro, Piga, Matteo, Drott, Ulrich, Delbrueck, Christiane, Bauhammer, Jutta, Cagnotto, Giovanni, Vancheri, Carlo, Sambataro, Gianluca, De Langhe, Ellen, Sainaghi, Pier Paolo, Monti, Cristina, Gigli Berzolari, Francesca, Romano, Mariaeva, Bonella, Francesco, Specker, Christof, Schwarting, Andreas, Villa Blanco, Ignacio, Selmi, Carlo, Ceribelli, Angela, Nuno, Laura, Mera-Varela, Antonio, Perez Gomez, Nair, Fusaro, Enrico, Parisi, Simone, Sinigaglia, Luigi, Del Papa, Nicoletta, Benucci, Maurizio, Cimmino, Marco Amedeo, Riccieri, Valeria, Conti, Fabrizio, Sebastiani, Gian Domenico, Iuliano, Annamaria, Emmi, Giacomo, Cammelli, Daniele, Sebastiani, Marco, Manfredi, Andreina, Bachiller-Corral, Javier, Sifuentes Giraldo, Walter Alberto, Paolazzi, Giuseppe, Saketkoo, Lesley Ann, Giorgi, Roberto, Salaffi, Fausto, Cifrian, Jose, Caporali, Roberto, Locatelli, Francesco, Marchioni, Enrico, Pesci, Alberto, Dei, Giulia, Pozzi, Maria Rosa, Claudia, Lomater, Distler, Jorg, Knitza, Johannes, Schett, George, Iannone, Florenzo, Fornaro, Marco, Franceschini, Franco, Quartuccio, Luca, Gerli, Roberto, Bartoloni, Elena, Bellando Randone, Silvia, Zampogna, Giuseppe, Gonzalez Perez, Montserrat I, Mejia, Mayra, Vicente, Esther, Triantafyllias, Konstantinos, Lopez-Mejias, Raquel, Matucci-Cerinic, Marco, Selva-O'Callaghan, Albert, Castañeda, Santos, Montecucco, Carlomaurizio, and Gonzalez-Gay, Miguel Angel

Abstract

Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung disease (ILD), along with specific autoantibodies that are addressed to different aminoacyl tRNA synthetases (ARS). Until now, it has been unknown whether the presence of a different ARS might affect the clinical presentation, evolution, and outcome of ASSD. In this study, we retrospectively recorded the time of onset, characteristics, clustering of triad findings, and survival of 828 ASSD patients (593 anti-Jo1, 95 anti-PL7, 84 anti-PL12, 38 anti-EJ, and 18 anti-OJ), referring to AENEAS (American and European NEtwork of Antisynthetase Syndrome) collaborative group's cohort. Comparisons were performed first between all ARS cases and then, in the case of significance, while using anti-Jo1 positive patients as the reference group. The characteristics of triad findings were similar and the onset mainly began with a single triad finding in all groups despite some differences in overall prevalence. The "ex-novo" occurrence of triad findings was only reduced in the anti-PL12-positive cohort, however, it occurred in a clinically relevant percentage of patients (30%). Moreover, survival was not influenced by the underlying anti-aminoacyl tRNA synthetase antibodies' positivity, which confirmed that antisynthetase syndrome is a heterogeneous condition and that antibody specificity only partially influences the clinical presentation and evolution of this condition.

Published
2019

242. Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology

Author

Butler, E-A, Baron, M, Fogo, AB, Frech, T, Ghossein, C, Hachulla, E, Hoa, S, Johnson, SR, Khanna, D, Mouthon, L, Nikpour, M, Proudman, S, Steen, V, Stern, E, Varga, J, Denton, C, Hudson, M, Barnado, A, Bernstein, EJ, Boin, F, Braun-Moscovici, Y, Castelino, FV, Catoggio, LJ, Matucci-Cerinic, M, Chung, L, Clements, P, Csuka, ME, De langhe, E, Distler, J, Distler, O, Farge, DC, Fischer, A, Gabrielli, A, Hasegawa, M, Hayat, S, Herrick, A, Hesselstrand, R, Hsu, V, Hughes, M, Hunzelmann, N, Hummers, L, Iannone, F, Ingegnoli, F, Jacobsen, S, Kawaguchi, Y, Koenig, M, Kuwana, M, Lenaerts, J, Martin, T, Mayes, MD, McMahan, Z, Medsger, T, Merkel, P, Narain, S, Ong, V, Pauling, JD, Pope, J, de la Puente, C, Rischmueller, M, Sofia Rodriguez-Reyna, T, Sahhar, J, Saketkoo, LA, Senecal, J-L, Shah, A, Shah, AA, Alberto Sifuentes-Giraldo, W, Silver, R, Stevens, W, Sutton, E, Thakkar, V, Valentini, G, de Vries-Bouwstra, J, Vonk, M, Walker, UA, Butler, E-A, Baron, M, Fogo, AB, Frech, T, Ghossein, C, Hachulla, E, Hoa, S, Johnson, SR, Khanna, D, Mouthon, L, Nikpour, M, Proudman, S, Steen, V, Stern, E, Varga, J, Denton, C, Hudson, M, Barnado, A, Bernstein, EJ, Boin, F, Braun-Moscovici, Y, Castelino, FV, Catoggio, LJ, Matucci-Cerinic, M, Chung, L, Clements, P, Csuka, ME, De langhe, E, Distler, J, Distler, O, Farge, DC, Fischer, A, Gabrielli, A, Hasegawa, M, Hayat, S, Herrick, A, Hesselstrand, R, Hsu, V, Hughes, M, Hunzelmann, N, Hummers, L, Iannone, F, Ingegnoli, F, Jacobsen, S, Kawaguchi, Y, Koenig, M, Kuwana, M, Lenaerts, J, Martin, T, Mayes, MD, McMahan, Z, Medsger, T, Merkel, P, Narain, S, Ong, V, Pauling, JD, Pope, J, de la Puente, C, Rischmueller, M, Sofia Rodriguez-Reyna, T, Sahhar, J, Saketkoo, LA, Senecal, J-L, Shah, A, Shah, AA, Alberto Sifuentes-Giraldo, W, Silver, R, Stevens, W, Sutton, E, Thakkar, V, Valentini, G, de Vries-Bouwstra, J, Vonk, M, and Walker, UA

Abstract

OBJECTIVE: To generate a core set of items to develop classification criteria for scleroderma renal crisis (SRC) using consensus methodology. METHODS: An international, multidisciplinary panel of experts was invited to participate in a 3-round Delphi exercise developed using a survey based on items identified by a scoping review. In round 1, participants were asked to identify omissions and clarify ambiguities regarding the items in the survey. In round 2, participants were asked to rate the validity and feasibility of the items using Likert-type scales ranging from 1 to 9 (where 1 = very invalid/unfeasible, 5 = uncertain, and 9 = very valid/feasible). In round 3, participants reviewed the results and comments from round 2 and were asked to provide final ratings. Items rated as highly valid and feasible (median scores ≥7 for each) in round 3 were selected as the provisional core set of items. A consensus meeting using a nominal group technique was conducted to further reduce the core set of items. RESULTS: Ninety-nine experts from 16 countries participated in the Delphi exercise. Of the 31 items in the survey, consensus was achieved on 13, in the categories hypertension, renal insufficiency, proteinuria, and hemolysis. Eleven experts took part in the nominal group technique discussion, where consensus was achieved in 5 domains: blood pressure, acute kidney injury, microangiopathic hemolytic anemia, target organ dysfunction, and renal histopathology. CONCLUSION: A core set of items that characterize SRC was identified using consensus methodology. This core set will be used in future data-driven phases of this project to develop classification criteria for SRC.

Published
2019

243. Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behçet’s disease

Author

Lopalco, G, Venerito, V, Leccese, P, Emmi, G, Cantarini, L, Lascaro, N, Di Scala, G, Fabiani, C, Rigante, Donato, Iannone, F, Rigante D (ORCID:0000-0001-7032-7779), Lopalco, G, Venerito, V, Leccese, P, Emmi, G, Cantarini, L, Lascaro, N, Di Scala, G, Fabiani, C, Rigante, Donato, Iannone, F, and Rigante D (ORCID:0000-0001-7032-7779)

Abstract

Relapsing oral and genital ulcers (OGUs) represent the stigmata of Behçet’s disease (BD) and may be very painful, affecting both quality of life and relationships. A wide number of topical and immunosuppressive drugs can be used to treat ulcers [1], but failures are commonly reported. The efficacy of the phosphodiesterase-4 inhibitor apremilast has been proven in OGUs of BD in two randomized clinical trials (RCT) [2, 3], whereas only two case reports are available until now [4, 5]. We aimed at evaluating the real-world effectiveness of apremilast in BD patients with OGUs refractory to conventional and/or biologic treatments. We retrospectively evaluated patients classified as BD, according to International Criteria for BD [6] and International Study Group [7] criteria, who underwent apremilast (30 mg twice daily) for multirefractory OGUs from November 2017 to January 2019. The number of OGUs was assessed at baseline and either at 3 and 6 months. Pain from ulcers and BD activity were evaluated via 100-mm visual-analogue scale (VAS) and BD Current Activity Form (BDCAF). We also recorded the number of oral and genital ulcer flares both in the 4 weeks prior to apremilast start and throughout the observation period (Table 1 and Supplementary Table 2). The occurrence of adverse events was also reported. Paired t-test or Wilcoxon matched-pair signed rank test were used for statistical analysis. The off-label use of apremilast was approved by the Hospital Ethics Committee in compliance with the Declaration of Helsinki. All patients provided a written informed consent. Thirteen patients (females 9/13) with disease duration (mean ± SD) of 154 ± 167 months were analysed (Table 1). At 3 months, (data from 12/13 patients) active OGUs were significantly less (p=0.02 for both) than baseline (Table 2). Three patients stopped the treatment due to diarrhoea. At 6 months, active oral ulcers and oral relapses were still lower than baseline (p=0.03 for both), whereas only a positive tr

Published
2019

244. Long-term retention rate of anakinra in adult onset Still’s disease and predictive factors for treatment response.

Author

Vitale, A, Cavalli, G, Colafrancesco, S, Priori, R, Valesini, G, Argolini, Lm, Baldissera, E, Bartoloni, E, Cammelli, D, Canestrari, G, Sota, J, Cavallaro, E, Massaro, Maria Grazia, Ruscitti, P, Cipriani, P, De Marchi, G, De Vita, S, Emmi, G, Ferraccioli, Gianfranco, Frassi, M, Gerli, R, Gremese, Elisa, Iannone, F, Lapadula, G, Lopalco, G, Manna, Raffaele, Mathieu, A, Montecucco, C, Mosca, M, Piazza, I, Piga, M, Pontikaki, I, Romano, M, Rossi, S, Rossini, M, Silvestri, E, Stagnaro, C, Talarico, R, Tincani, A, Viapiana, O, Vitiello, G, Galozzi, P, Sfriso, P, Gaggiano, C, Rigante, Donato, Dagna, L, Giacomelli, R, Cantarini, L, Ferraccioli G (ORCID:0000-0001-6246-2428), Gremese E (ORCID:0000-0002-2248-1058), Manna R (ORCID:0000-0003-1560-3907), Rigante D (ORCID:0000-0001-7032-7779), Vitale, A, Cavalli, G, Colafrancesco, S, Priori, R, Valesini, G, Argolini, Lm, Baldissera, E, Bartoloni, E, Cammelli, D, Canestrari, G, Sota, J, Cavallaro, E, Massaro, Maria Grazia, Ruscitti, P, Cipriani, P, De Marchi, G, De Vita, S, Emmi, G, Ferraccioli, Gianfranco, Frassi, M, Gerli, R, Gremese, Elisa, Iannone, F, Lapadula, G, Lopalco, G, Manna, Raffaele, Mathieu, A, Montecucco, C, Mosca, M, Piazza, I, Piga, M, Pontikaki, I, Romano, M, Rossi, S, Rossini, M, Silvestri, E, Stagnaro, C, Talarico, R, Tincani, A, Viapiana, O, Vitiello, G, Galozzi, P, Sfriso, P, Gaggiano, C, Rigante, Donato, Dagna, L, Giacomelli, R, Cantarini, L, Ferraccioli G (ORCID:0000-0001-6246-2428), Gremese E (ORCID:0000-0002-2248-1058), Manna R (ORCID:0000-0003-1560-3907), and Rigante D (ORCID:0000-0001-7032-7779)

Abstract

We have evaluated long-term retention rate of anakinra in adult onset Still disease and predictive factors for treatment response. The risk of losing anakinra efficacy increases along with the number of swollen joints at the start of therapy, while the typical skin rash is a negative predictor of anakinra withdrawal.

Published
2019

245. Unveiling the efficacy, safety, and tolerability of anti-interleukin-1 treatment in monogenic and multifactorial autoinflammatory diseases

Author

Bettiol, A, Lopalco, G, Emmi, G, Cantarini, L, Urban, Ml, Vitale, A, Denora, N, Lopalco, A, Cutrignelli, A, Lopedota, A, Venerito, V, Fornaro, M, Vannacci, A, Rigante, Donato, Cimaz, R, Iannone, F, Rigante D (ORCID:0000-0001-7032-7779), Bettiol, A, Lopalco, G, Emmi, G, Cantarini, L, Urban, Ml, Vitale, A, Denora, N, Lopalco, A, Cutrignelli, A, Lopedota, A, Venerito, V, Fornaro, M, Vannacci, A, Rigante, Donato, Cimaz, R, Iannone, F, and Rigante D (ORCID:0000-0001-7032-7779)

Abstract

Autoinflammatory diseases (AIDs) are a heterogeneous disorders caused by overproduction of interleukin (IL)-1. Appropriate treatment is crucial, also considering that AIDs may persist into adulthood with negative consequences on patients’ quality of life. IL-1 blockade results in a sustained reduction of disease severity in most AIDs. A growing experience with the human IL-1 receptor antagonist anakinra (ANA) and the monoclonal anti IL-1 antibody canakinumab (CANA) has been engendered, highlighting their efficacy upon protean clinical manifestations of AIDs. Safety and tolerability have been confirmed by several clinical trials and observational studies on both large and small cohorts of AID patients. The same treatment has been proposed in refractory Kawasaki disease, an acute inflammatory vasculitis occurring in children before 5 years which has been postulated to be autoinflammatory for its phenotypical and immunological similarity with systemic juvenile idiopathic arthritis. Nevertheless, minor concerns about IL-1 antagonists have been raised regarding their employment in children, and the development of novel pharmacological formulations is aimed at minimizing side effects that may affect adherence to treatment. The present review summarizes all current findings on the efficacy, safety and tolerability of ANA and CANA for treatment of AIDs and Kawasaki vasculitis with specific focusing on pediatric setting.

Published
2019

250. Overview of the FTU results

Author

Pucella, G, Alessi, E, Amicucci, L, Angelini, B, Apicella, Ml, Apruzzese, G, Artaserse, G, Belli, F, Bin, W, Boncagni, L, Botrugno, A, Briguglio, S, Bruschi, A, Buratti, P, Calabrò, G, Cappelli, M, Cardinali, A, Castaldo, C, Causa, F, Ceccuzzi, S, Centioli, C, Cesario, R, Cianfarani, C, Claps, G, Cocilovo, V, Cordella, F, Crisanti, F, D'Arcangelo, O, De Angeli, M, Di Troia, C, Esposito, B, Farina, D, Figini, L, Fogaccia, G, Frigione, D, Fusco, V, Gabellieri, L, Garavaglia, S, Giovannozzi, E, Granucci, G, Iafrati, M, Iannone, F, Lontano, M, Maddaluno, G, Magagnino, S, Marinucci, M, Marocco, D, Mazzitelli, G, Mazzotta, C, Milovanov, A, Minelli, D, Mirizzi, Fc, Moro, A, Nowak, S, Pacella, D, Panaccione, L, Panella, M, Pericoli-Ridolfini, V, Pizzuto, A, Podda, S, Ramogida, G, Ravera, G, Ricci, D, Romano, A, Sozzi, C, Tuccillo, Aa, Tudisco, O, Viola, B, Vitale, V, Vlad, G, Zerbini, M, Zonca, F, Aquilini, M, Cefali, P, Ferdin, D, O, E, Di Giovenale, S, Giacomi, G, Grosso, A, Mellera, V, Mezzacappa, M, Pensa, A, Petrolini, P, Piergotti, V, Raspante, B, Rocchi, G, Sibio, A, Tilia, B, Tulli, R, Vellucci, M, Zannetti, D, Bogdanovic-Radovic, I, Carnevale, D, Casolari, A, Ciotti, M, Conti, C, Dinca, Pp, Dolci, V, Galperti, C, Gospodarczyk, M, Grosso, G, Lubiako, L, Lungu, M, Martin-Solis, Jr, Meineri, C, Murtas, F, Nardone, A, Orsitto, Fp, Perelli Cippo, E, Popovic, Z, Ripamonti, D, Simonetto, A, Tartari, U, European Commission, Meineri, C., Dolci, V., Ciotti, M., Zannetti, D., Vellucci, M., Tulli, R., Tilia, B., Sibio, A., Rocchi, G., Raspante, B., Piergotti, V., Petrolini, P., Pensa, A., Mezzacappa, M., Grosso, A., Giacomi, G., Di Giovenale, S., Di Ferdinando, E., Cefali, P., Aquilini, M., Zonca, F., Zerbini, M., Vlad, G., Vitale, V., Viola, B., Tudisco, O., Tuccillo, A. A., Romano, A., Ravera, G., Ramogida, G., Podda, S., Pizzuto, A., Pacella, D., Milovanov, A., Mazzotta, C., Mazzitelli, G., Marocco, D., Marinucci, M., Maddaluno, G., Iannone, F., Iafrati, M., Giovannozzi, E., Gabellieri, L., Fusco, V., Frigione, D., Fogaccia, G., Esposito, B., Di Troia, C., D'Arcangelo, O., Crisanti, F., Cordella, F., Cocilovo, V., Claps, G., Cianfarani, C., Cesario, R., Centioli, C., Ceccuzzi, S., Causa, F., Castaldo, C., Cardinali, A., Cappelli, M., Calabrò, G., Buratti, P., Briguglio, S., Botrugno, A., Boncagni, L., Belli, F., Artaserse, G., Apruzzese, G., Apicella, M. L., Angelini, B., Amicucci, L., and Pucella, G.

Subjects
tokamak, FTU, overview, Nuclear and High Energy Physics, Tokamak FTU, Física, Condensed Matter Physics, 01 natural sciences, 7. Clean energy, 010305 fluids & plasmas, Runaway electrons, Settore ING-INF/04 - Automatica, 0103 physical sciences, tokamak, overview, FTU, 010306 general physics, Tokamak plasmas
Abstract

Experiments on runaway electrons have been performed for the determination of the critical electric field for runaway generation. A large database of post-disruption runaway beams has been analyzed in order to identify linear dynamical models for new position and current runaway beam controllers, and experiments of electron cyclotron assisted plasma start-up have shown the presence of runaway electrons also below the expected electric field threshold, indicating that the radio-frequency power acts as seeding for fast electrons. A linear micro-stability analysis of neon-doped pulses has been carried out to investigate the mechanisms leading to the observed density peaking. A study of the ion drift effects on the MARFE instability has been performed and the peaking of density profile in the high density regime has been well reproduced using a thermo-diffusive pinch in the particle transport equation. The study of the density limit performed in the past has been extended towards lower values of toroidal magnetic field and plasma current. The analysis of the linear stability of the 2/1 tearing mode observed in high density plasmas has highlighted a destabilization with increasing peaking of the current profile during the density ramp-up, while the final phase of the mode temporal evolution is characterized by limit cycles on the amplitude/frequency plane. A liquid lithium limiter with thermal load capability up to 10 MW m−2 has been tested. The pulse duration has been extended up to 4.5 s and elongated configurations have been obtained for 3.5 s, with the X-point just outside the plasma chamber. A W/Fe sample has been exposed in the scrape-off layer in order to study the sputtering of Fe and the W enrichment of the surface layer. Dusts have been collected and analyzed, showing that the metallic population exhibits a high fraction of magnetic grains. A new diagnostic for in-flight runaway electron studies has allowed the image and the visible/infrared spectrum of the forward and backward synchrotron radiation to be provided simultaneously. A fast infrared camera for thermo-graphic analysis has provided the pattern of the toroidal limiter heating by disruption heat loads, and a triple-GEM detector has been tested for soft x-ray diagnostics. The collective Thomson scattering diagnostic has been upgraded and used for investigations on parametric decay instability excitation by electron cyclotron beams correlated with magnetic islands, and new capabilities of the Cherenkov probe have been explored in the presence of beta-induced Alfvén eigenmodes associated to high amplitude magnetic islands. This work has been carried out within the framework of the EUROfusion Consortium and has received funding from the Euratom research and training programme 2014-2018 under grant agreement No 633053. The views and opinions expressed herein do not necessarily reflect those of the European Commission. Publicado

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results